Intel, with declining revenues, margins, and asset efficiency, faces significant challenges. Despite restructuring efforts, Intel's financial performance continues to decline, with FY24 revenues down 33% from FY21 and net income turning negative. A sum of parts of three independent units - Intel Products, Intel Foundry, and Architecture Design - points to significant shareholder value, with a potential total market cap of $393 billion.
Selling put options on Intel and CRISPR Therapeutics could yield high returns with only moderate risk, given their respective market conditions and potential upside. For Intel, selling $22 strike June 20th puts offers a 19.07% annualized yield, with a -19.8% breakeven, supported by strong fundamentals and a new CEO. For CRISPR, selling $30 strike July 18th puts offers a 13.51% annualized yield, with a -29% breakeven, backed by a promising biotech pipeline and recent drug approval.
This week, new Intel (INTC) CEO Lip-Bu Tan officially took the reins at the chip giant this week. But there is still a lot of uncertainty about what lies ahead for the chipmaker.
Nvidia CEO Jensen Huang said on Wednesday that his company has not been approached about purchasing a stake in Intel.
Intel (INTC -6.75%) stock is seeing a big sell-off in Wednesday's trading due to chip foundry news. The semiconductor company's share price was down 7.1% as of 3 p.m.
Intel's new CEO, Lip-Bu Tan, has a stellar track record and is expected to drive a significant turnaround, making Intel a Strong Buy. INTC's Foundry Services, if successful, could rival TSMC, potentially boosting Intel's market share and valuation significantly. Despite recent struggles, the Company's vertically integrated business model and substantial investments in R&D position it for long-term growth.
Shares are up 25% since the chip maker announced Lip-Bu Tan as its chief executive.
This is technically, turnaround Tuesday. And yet, I struggled to find something that is truly turning around.
Despite excitement over Intel's new CEO, shares are still below the company's year-to-date highs — in February, when investors were expecting an imminent breakup.
Spotting a bargain in the stock market isn't as easy as it looks. There's a difference between "cheap looking" and cheap.
A potential joint venture between Intel and TSMC, and some of its clients, could help the chipmaker mitigate losses in its foundry business, which lost $13.4B in FY 2024. Intel's restructuring has heavily weighed on its profitability as well as the chipmaker's valuation. IFS is losing money hand over fist, and a strategic deal may be required in order to stop the bleeding for Intel and its shareholders.
Shares of Intel Corporation (NASDAQ:INTC) rose more than 8% in early-morning trading on Monday on news that incoming CEO Lip-Bu Tan has big plans to turn around the ailing chipmaker, including restructuring the company's approach to AI, resurrecting its manufacturing operations, and eyeing cuts to what Tan views as a “slow-moving and bloated middle-management layer,” according to a Reuters report.